The combination therapy can be used as first-line treatment for unresectable or metastatic forms of the cancer.

The Food and Drug Administration (FDA) has approved Opdivo ® (nivolumab) in combination with Yervoy ® (ipilimumab) for the first-line treatment of adult patients with unresectable or metastatic ...

The US Food and Drug Administration (FDA) has granted approval for Bristol Myers Squibb’s (BMS) Opdivo (nivolumab) in ...

Randomized controlled trials are also needed to determine whether statins can actually reduce the risk for hepatocellular carcinoma and hepatic decompensation in patients with chronic liver disease, ...

Given the success of Research Topic <a href=" in Chemotherapy-Resistant Hepatocellular Carcinoma and the rapidly evolving ...

Findings from the CheckMate 9DW trial support the FDA approval of nivolumab and ipilimumab in unresectable hepatocellular ...

Advanced hepatocellular carcinoma (HCC) with pulmonary metastasis (PM) has a poor prognosis, and optimal treatment strategies remain controversial. This study compared pulmonary metastasectomy and ...

Researchers sought to test the performance of a deep learning model system using longitudinal magnetic resonance imaging (MRI) in predicting early recurrence in patients with hepatocellular carcinoma.

This is called secondary liver cancer or liver metastases. Hepatocellular carcinoma is also called hepatoma or HCC. It's the most common type of primary liver cancer. Because of this, the information ...

David M. Dudzinski: A 59-year-old man with a history of obesity, dyslipidemia, and hypertension was evaluated in the oncology clinic of this hospital because of hepatocellular carcinoma.